Lv1
40 积分 2025-07-13 加入
Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown
2天前
已完结
Lifestyle interventions for cardiometabolic health
3个月前
已完结
Trends and Disparities in Newer GLP1 Receptor Agonist Initiation among Real-World Adult Patients Eligible for Obesity Treatment
3个月前
已关闭
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
4个月前
已完结
Retatrutide: a triple incretin receptor agonist for obesity management
4个月前
已完结
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
4个月前
已完结
Medications for Obesity
4个月前
已完结
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
8个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
8个月前
已完结
Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation
9个月前
已完结
皖公网安备34019202002308
